Radius starts Ppase 2a trial of RAD1901 in menopausal hot flashes

[News]

Radius Health ("Radius") announced today that the first patient has been dosed in the company's proof-of-concept Phase 2a study of RAD1901, an investigational selective estrogen receptor modulator (SERM) undergoing clinical evaluation for treatment of vasomotor symptoms (menopausal hot flashes).

More... (http://www.news-medical.net/?id=47332)